Advancing the disease management of Atopic Dermatitis in the new era

17 July 2025

Dr Lai Yik Kiu Dominic
MBBS (HKU) , MRCP (UK) , FHKCP, FHKAM (Medicine) , DCH (Lond) , M Sc in Dermatology (Cardiff)

Abstract

Atopic dermatitis (AD) management has shifted from broad, non-specific symptom control to precision medicine driven by targeted biologics (e.g., dupilumab, lebrikizumab, nemolizumab) or a once-daily, oral Janus kinase inhibitor (JAK inhibitors e.g., upadacitinib, abrocitinib). This new era transforms care from temporary relief to disease modification, emphasizing rapid itch reduction and long-term, steroid-sparing remission.